Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
FMR LLC filed an amendment to Schedule 13G/A reporting 9,252,159.10 shares of Nuvalent Inc. Class A common stock, representing 12.6% of the class. The filing lists sole dispositive power of 9,252,159.10 shares and sole voting power of 9,236,172. The filing names Abigail P. Johnson in relation to the holding and references an attached 13d-1(k) agreement in Exhibit 99.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported a mix of stock option exercises and share sales in Class A common stock. On May 1, 2026, she exercised options to acquire a total of 11,430 shares through two transactions at exercise prices of $6.89 and $1.08 per share.
On the same date, Balcom sold an aggregate of 11,430 shares in open-market transactions at weighted average prices of about $98–$100 per share, with individual sale prices ranging from $97.84 to $100.36. The filing notes these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the timing of the sales was set in advance.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. On April 30, 2026, she sold 1,082 Class A common shares at a weighted average price of $99.57 and 4,418 shares at a weighted average price of $99.13 in open-market sales.
On the same date, she exercised options to acquire 5,500 Class A common shares at an exercise price of $6.89 per share from a fully vested option grant. After these transactions, she directly holds 59,634 Class A common shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported an exercise-and-sell transaction in Class A Common Stock. On April 29, 2026, she exercised 5,500 stock options at $27.85 per share and sold 5,500 shares in multiple open‑market trades around the $99–$101 range. After these transactions, she directly held 58,117 shares of Class A Common Stock. The filing notes the trades were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2024, indicating the timing was set in advance.
NUVL listed a Form 144 notice to sell 16,500 shares of Common Stock. The filing states the shares relate to an exercise of stock options and lists an aggregate value of $1,635,150.00. The filing also records two recent 10b5-1 sales of 5,500 shares each on 03/26/2026 and 02/26/2026. Shares outstanding are shown as 73,181,747 as of 04/30/2026.
Nuvalent, Inc. is holding its 2026 annual meeting of stockholders virtually on June 16, 2026, at 2:00 p.m. Eastern Time. Holders of 73,542,756 shares of Class A common stock as of April 20, 2026 may vote online using a 16-digit control number.
Stockholders will vote on electing two Class II directors, an advisory “say‑on‑pay” resolution covering named executive officer compensation, and ratifying KPMG LLP as independent auditor for 2026. The proxy also highlights 2025 progress, including FDA filings for zidesamtinib and neladalkib and a $500 million public offering.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares in a planned transaction. On April 9, 2026, he exercised options to acquire 3,093 shares of Class A common stock at an exercise price of $27.85 per share.
That same day, he sold 2,193 shares at a weighted average price of $104.27 and 900 shares at a weighted average price of $105.00 under a Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, he held 65,604 shares of Class A common stock directly.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving company stock. He exercised stock options covering 13,714 shares of Class A Common Stock at an exercise price of $18.93 per share and 16,286 shares at $27.85 per share, acquiring 30,000 shares in total. On the same date, he sold 30,000 shares of Class A Common Stock in open-market transactions at prices reported as $103.21, $103.78, $104.78 and $105.60 per share. According to a footnote, these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. Following the transactions, he directly held 324,879 shares of Nuvalent Class A Common Stock.
Nuvalent, Inc. reported that on April 7, 2026 it announced submitting a New Drug Application to the U.S. Food and Drug Administration for neladalkib. The application covers use in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer.
This step moves neladalkib from clinical development into formal regulatory review, an important stage toward potential U.S. market availability if the FDA later approves the drug.